The Moral Case for and Against Compensated Egg Donation

Abstract

Compensated oocyte donation sits at the intersection of two well-established but conflicting ethical intuitions: that competent adults may be paid for burdensome, risky labor, and that the human body and its reproductive material should not be treated as market commodities. This perspective sets out the strongest versions of both the autonomy-and-fair-labor case for compensation and the commodification-and-exploitation case against it, drawing on the reproductive ethics and empirical donor-experience literature. We examine the evidence on donor health risk and informed consent, which remains thinner than either side's arguments generally assume, and compare three regulatory approaches now in use: market-rate compensation, capped or state-set compensation, and altruism-only reimbursement. None of the three models fully reconciles fair treatment of donors with protection against undue inducement and structural inequity in who supplies eggs. We conclude that a defensible policy likely requires compensation that is decoupled from donor traits, combined with a substantially stronger long-term evidence base on donor health outcomes than currently exists.